These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 23135024

  • 21. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
    Siller S, Lauseker M, Karschnia P, Niyazi M, Eigenbrod S, Giese A, Tonn JC.
    Acta Neuropathol Commun; 2021 Mar 04; 9(1):35. PubMed ID: 33663593
    [Abstract] [Full Text] [Related]

  • 22. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA, French PJ.
    Clin Cancer Res; 2011 Nov 15; 17(22):7148-55. PubMed ID: 21914791
    [Abstract] [Full Text] [Related]

  • 23. MGMT gene promoter methylation in pediatric glioblastomas.
    Srivastava A, Jain A, Jha P, Suri V, Sharma MC, Mallick S, Puri T, Gupta DK, Gupta A, Sarkar C.
    Childs Nerv Syst; 2010 Nov 15; 26(11):1613-8. PubMed ID: 20585787
    [Abstract] [Full Text] [Related]

  • 24. MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.
    Lattanzio L, Borgognone M, Mocellini C, Giordano F, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Ghiglia A, Fillini C, Bernucci C, Merlano M, Lo Nigro C.
    Int J Biol Markers; 2015 May 26; 30(2):e208-16. PubMed ID: 25588856
    [Abstract] [Full Text] [Related]

  • 25. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
    Kakkar A, Kumar A, Jha P, Goyal N, Mallick S, Sharma MC, Suri A, Singh M, Kale SS, Julka PK, Sarkar C, Suri V.
    Neuropathology; 2014 Aug 26; 34(4):333-42. PubMed ID: 24521400
    [Abstract] [Full Text] [Related]

  • 26. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G, Mallick S, Sharma V, Joshi N, Purkait S, Jha P, Sharma MC, Suri V, Julka PK, Mahapatra AK, Singh M, Kale SS, Sarkar C.
    Neuropathology; 2012 Oct 26; 32(5):534-42. PubMed ID: 22380407
    [Abstract] [Full Text] [Related]

  • 27. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
    Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, Weller M, German Glioma Network.
    Int J Cancer; 2012 Sep 15; 131(6):1342-50. PubMed ID: 22139906
    [Abstract] [Full Text] [Related]

  • 28. O⁶-methylguanine-DNA-methyltransferase promoter methylation assessment by microdissection-assisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas.
    Yang SH, Lee KS, Yang HJ, Jeon BH, Lee YS, Nam SW, Chung DS, Lee SW, Hong YK.
    J Neurooncol; 2012 Jan 15; 106(2):243-50. PubMed ID: 21792731
    [Abstract] [Full Text] [Related]

  • 29. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY, Jung S, Moon KS, Kim IY, Kang SS, Kim YH, Park CS, Lee KH.
    Oncol Rep; 2010 May 15; 23(5):1269-76. PubMed ID: 20372840
    [Abstract] [Full Text] [Related]

  • 30. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A.
    Oncotarget; 2015 Oct 06; 6(30):29285-95. PubMed ID: 26320189
    [Abstract] [Full Text] [Related]

  • 31. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK.
    Clin Cancer Res; 2008 May 01; 14(9):2664-72. PubMed ID: 18451230
    [Abstract] [Full Text] [Related]

  • 32. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
    Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, Sommer C, Kaina B.
    Int J Cancer; 2010 Nov 01; 127(9):2106-18. PubMed ID: 20131314
    [Abstract] [Full Text] [Related]

  • 33. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism.
    Candiloro IL, Dobrovic A.
    Cancer Prev Res (Phila); 2009 Oct 01; 2(10):862-7. PubMed ID: 19789298
    [Abstract] [Full Text] [Related]

  • 34. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.
    Kanemoto M, Shirahata M, Nakauma A, Nakanishi K, Taniguchi K, Kukita Y, Arakawa Y, Miyamoto S, Kato K.
    BMC Cancer; 2014 Aug 30; 14():641. PubMed ID: 25175833
    [Abstract] [Full Text] [Related]

  • 35. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
    Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Meyerhardt JA, Hunter DJ, Fuchs CS.
    Carcinogenesis; 2007 Sep 30; 28(9):1985-90. PubMed ID: 17621591
    [Abstract] [Full Text] [Related]

  • 36. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
    Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M.
    PLoS One; 2012 Sep 30; 7(3):e33449. PubMed ID: 22428052
    [Abstract] [Full Text] [Related]

  • 37. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
    Lee A, Youssef I, Osborn VW, Safdieh J, Becker DJ, Schreiber D.
    J Clin Neurosci; 2018 May 30; 51():85-90. PubMed ID: 29483008
    [Abstract] [Full Text] [Related]

  • 38. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
    Hsu CY, Lin SC, Ho HL, Chang-Chien YC, Hsu SP, Yen YS, Chen MH, Guo WY, Ho DM.
    Am J Surg Pathol; 2013 Feb 30; 37(2):264-71. PubMed ID: 23282970
    [Abstract] [Full Text] [Related]

  • 39. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.
    Everhard S, Tost J, El Abdalaoui H, Crinière E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Thillet J.
    Neuro Oncol; 2009 Aug 30; 11(4):348-56. PubMed ID: 19224763
    [Abstract] [Full Text] [Related]

  • 40. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
    Sasai K, Nodagashira M, Nishihara H, Aoyanagi E, Wang L, Katoh M, Murata J, Ozaki Y, Ito T, Fujimoto S, Kaneko S, Nagashima K, Tanaka S.
    Am J Surg Pathol; 2008 Aug 30; 32(8):1220-7. PubMed ID: 18580490
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.